Takeda Pharmaceutical Company Limited (FRA:TKDA)

Germany flag Germany · Delayed Price · Currency is EUR
13.80
+0.20 (1.47%)
At close: Jan 27, 2026
9.52%
Market Cap45.16B +11.9%
Revenue (ttm)24.25B -2.5%
Net Income613.43M -45.7%
EPS0.38 -45.9%
Shares Outn/a
PE Ratio73.62
Forward PEn/a
Dividend0.50 (3.64%)
Ex-Dividend DateSep 30, 2025
Volumen/a
Average Volume6
Open13.80
Previous Close13.60
Day's Range13.80 - 13.80
52-Week Range11.30 - 14.00
Betan/a
RSI69.67
Earnings DateJan 29, 2026

About FRA:TKDA

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TKDA
Full Company Profile

Financial Performance

In fiscal year 2025, FRA:TKDA's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements